Results 11 to 20 of about 1,534 (92)

Chelator-facilitated removal of iron from transferrin: Relevance to combined chelation therapy [PDF]

, 2008
Current iron chelation therapy consists primarily of DFO (desferrioxamine), which has to be administered via intravenous infusion, together with deferiprone and deferasirox, which are orally-active chelators.
Evans, PJ, Evans, RW, Hider, RC, Devanur, LD   +3 more
core   +7 more sources

Trial of Deferiprone in Parkinson\u27s Disease

, 2022
\ua9 2022 Massachusetts Medical Society. Background Iron content is increased in the substantia nigra of persons with Parkinson\u27s disease and may contribute to the pathophysiology of the disorder.
Ory-Magne F, Dexter DT, Labreuche J, Spino M, Maetzler W, Mangin J-F, Poewe W, Ouk T, Otto M, Chupin M, Thobois S, Lopes R, Pruvo J-P, Deplanque D, Ruzicka E, Fradette C, Cabantchik I, Habert M-O, Berg D, Bordet R, Kuchcinski G, Duhamel A, Moreau C, Gago M, Tranchant C, Nyholm D, Coelho MVS, Lehericy S, Behnke S, Garcon G, Devedjian J-C, Walter U, Tricta F, Compta Y, Post B, Corvol J-C, Rolland A-S, Worth P, Pavese N, Viard R, Marques A-R, Bush AI, Devos D, Carpentier J, Leclercq C, Kulisevsky J, Duce JA, Simonin O, Pigny P, Scherfler C, Potey C, Meissner WG, Ayton S, Rascol O, Dusek P, Ferreira J, De Bie RMA, Vilas D, Defebvre L, Dodel R, Eusebio A, Delannoy PG, Januario C, Bloem BR, Seppi K   +64 more
core   +4 more sources

Trial of Deferiprone in Parkinson's Disease [PDF]

, 2022
BACKGROUND: Iron content is increased in the substantia nigra of persons with Parkinson's disease and may contribute to the pathophysiology of the disorder.
Devos, D., Dušek, Petr, Habert, M.O., Post, Bart, Meissner, Wassilios G., Habert, Marie-Odile, Labreuche, J., Bordet, Régis, Pruvo, J.P., Leclercq, C., Bush, Ashley I, Dodel, R., Poewe, W., Tricta, F., Leclercq, C. line, Marques, A.R., Pavese, Nicola, Bloem, Bastiaan R., Viard, Romain, Rolland, A.S., Scherfler, Christoph, Deplanque, D., Fradette, Caroline, Meissner, W.G., Vilas, D., Maetzler, Walter, Kuchcinski, G., Tranchant, Christine, Dušek, P., Růžička, E., Dexter, D.T., Otto, Markus, Corvol, Jean-Christophe, Moreau, Caroline, Bloem, Bastiaan R, Ruzička, EvÅen, Kulisevsky, J., Carpentier, J., Guyon Delannoy, Pauline, de Bie, Rob M.A., Rascol, O., Moreau, C., Coelho, Miguel V.S., Compta, Yaroslau, Spino, Michael, Januario, Cristina, Kuchcinski, Gregory, Duce, James A, Bush, Ashley I., Worth, Paul, Nyholm, Dag, Seppi, K., Garçon, G., Pigny, P., Maetzler, W., Gago, Miguel, Mangin, Jean-François, Leclercq, Céline, Lehericy, S., Ory-Magne, Fabienne, Ory-Magne, F., Behnke, S., Mangin, J.F., Ferreira, Joaquim, Walter, U., Simonin, O., Duhamel, Alain, Eusebio, A., Corvol, J.C., Devedjian, Jean-Christophe, Rascol, Olivier, Coelho, Miguel V S, Dexter, David T., Pruvo, Jean-Pierre, Pigny, Pascal, Duhamel, A., Walter, Uwe, Ferreira, J., Bordet, R., Chupin, M., Viard, R., Pavese, N., Vilas, Dolores, Simonin, Ophélie, Post, B., Potey, C., Ayton, S., Bush, A.I., Duce, J.A., Devos, David, Růžička, Evžen, Fradette, C., Compta, Y., Tricta, Fernando, Berg, D., Tranchant, C., Berg, Daniela, Ayton, Scott, Lehericy, Stéphane, Deplanque, Dominique, Devedjian, J.C., Cabantchik, I., Dodel, Richard, Delannoy, P. Guyon, Garçon, Guillaume, Labreuche, Julien, Poewe, Werner, Thobois, Stéphane, Januario, C., Lopes, Renaud, Ouk, Thavarak, Coelho, M.V.S., Meissner, Wassilios G, Scherfler, C., Lopes, R., Spino, M., Otto, M., Chupin, Marie, Eusebio, Alexandre, Defebvre, Luc, Barone, P, de Bie, Rob M. A., de Bie, Rob M A, Nyholm, Dag,, Defebvre, L., Behnke, Stefanie, Seppi, Klaus, Kulisevsky, Jaime, Ouk, T., Bloem, B.R., Bie, R.M. de, Cabantchik, Ioav, Dexter, David T, Bordet, R. gis, Carpentier, Jessica, Thobois, S., Coelho, Miguel V. S., Worth, P., Duce, James A., Delannoy, Pauline Guyon, Gago, M., Rolland, Anne-Sophie, Marques, Ana-Raquel, Nyholm, D., Potey, Camille   +144 more
core   +1 more source

Novel Antidepressant-Like Properties of the Iron Chelator Deferiprone in a Mouse Model of Depression

, 2022
Depressed individuals who carry the short allele for the serotonin-transporter-linked promotor region of the gene are more vulnerable to stress and have reduced response to first-line antidepressants such as selective serotonin reuptake inhibitors. Since
Hale, MW, Aitken, C, Uzungil, V, Tran, H, Bush, AI, Renoir, T, Payet, JM, Wilson, C, Opazo, CM, Li, S, Mawal, CH, Hannan, AJ   +11 more
core   +2 more sources

Antiplatelet activity of deferiprone through cyclooxygenase-1 inhibition

, 2020
Thalassemia patients are susceptible to both iron overload and thromboembolism. Deferiprone is an iron chelator that shows an antiplatelet activity and thus may alleviate platelet hyperactivation in thalassemia.
Noppawan Phumala Morales, Ponlapat Rojnuckarin, Rataya Luechapudiporn, Ngan Thi Tran, Benjaporn Akkawat   +4 more
core   +1 more source

Effect of deferiprone on cell cytotoxicity.

, 2015
(A) Light microscopic images on day 0 shows an equal number of PBMCs for each group. (B) LDH release by PBMC after treatment with deferiprone for 8 days.
Oleg Karaduta (787139), Judit K. Megyesi (456448), Sudhir V. Shah (787136), Kim M. Hiatt (787137), Chhanda Bose (787135), Kimberly A. Hall (787138), Sundararaman Swaminathan (787140)   +6 more
core   +1 more source

Deferiprone-induced arthropathy in thalassemia: MRI findings in a case

, 2009
Arthropathy is a well known side effect of the iron chelator deferiprone (L1); however, the imaging findings in deferiprone-induced arthropathy are not well known.
A Manchanda, Gyan Chand, Veena Chowdhury, Sapna Singh   +3 more
core   +1 more source

From Common Pathway to Divergent Diseases: Metabolic Aspects of Inborn Errors of CoA Biosynthesis

Journal of Inherited Metabolic Disease, Volume 49, Issue 5, September 2026.
ABSTRACT Coenzyme A (CoA) biosynthesis is a conserved, dynamically regulated pathway essential for mitochondrial energy production, fatty acid oxidation, lipid biosynthesis and protein acylation. Biallelic variants in PANK2, PPCS, PPCDC, and COASY cause rare inborn errors of CoA biosynthesis, associated with markedly different clinical phenotypes ...
Ivano Di Meo, Yair Anikster, Valeria Tiranti, Arcangela Iuso   +3 more
wiley   +1 more source

Cell Death in Neurodegenerative Diseases: Molecular Mechanisms and Therapeutic Targets

MedComm, Volume 7, Issue 9, September 2026.
Regulated cell death pathways, including apoptosis, necroptosis, pyroptosis, ferroptosis, and autophagy‐dependent cell death, interact with mitochondrial dysfunction, proteostasis failure, lysosomal stress, glial remodeling, and neuroinflammation across major neurodegenerative diseases.
Tianjiao Li, Qian Zhang, Yichen Wu, Ruixue Huang   +3 more
wiley   +1 more source

Amphetamine-like Deferiprone and Clioquinol Derivatives as Iron Chelating Agents [PDF]

The accumulation of iron in dopaminergic neurons can cause oxidative stress and dopaminergic neuron degeneration. Iron chelation therapy may reduce dopaminergic neurodegeneration, but chelators should be targeted towards dopaminergic cells. In this work,
Tristan Rawling, Katie A. Wilson, Mahmoud El Safadi, Mohan Bhadbhade, Andrew M. McDonagh, Megan L. O’Mara, Indigo J. Strudwicke   +6 more
core   +2 more sources